MedTrace Logo

Optimising Outpatient Care in Mild to Moderate Psoriasis (PSO-TOP)

NCT01587755 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1852

Last updated 2015-03-09

No results posted yet for this study

Summary

A Topical Treatment Optimisation Programme (TTOP) has been developed by the sponsor together with Patient Boards and an Expert Advisory Board to overcome non-adherence problems.

Conditions

  • Mild to Moderate Psoriasis

Interventions

OTHER

TTOP

Patient is taken care of in an intensified, optimised manner

OTHER

non-TTOP

Standard medical care

Sponsors & Collaborators

  • LEO Pharma

    collaborator INDUSTRY

  • Kristian Reich, MD

    lead INDIV

Principal Investigators

  • Kristian Reich, MD Prof.

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Denmark
  • France
  • Germany
  • Italy
  • Netherlands
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01587755 on ClinicalTrials.gov